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Abstract
Background: Autologous chondrocyte implantation (ACI) can be used in the treatment of focal cartilage injuries to
prevent the onset of osteoarthritis (OA). However, we are yet to understand fully why some individuals do not
respond well to this intervention. Identification of a reliable and accurate biomarker panel that can predict which
patients are likely to respond well to ACI is needed in order to assign the patient to the most appropriate therapy.
This study aimed to compare the baseline and mid-treatment proteomic profiles of synovial fluids (SFs) obtained
from responders and non-responders to ACI.
Methods: SFs were derived from 14 ACI responders (mean Lysholm improvement of 33 (17–54)) and 13 non-
responders (mean Lysholm decrease of 14 (4–46)) at the two stages of surgery (cartilage harvest and chondrocyte
implantation). Label-free proteome profiling of dynamically compressed SFs was used to identify predictive markers
of ACI success or failure and to investigate the biological pathways involved in the clinical response to ACI.
Results: Only 1 protein displayed a ≥2.0-fold differential abundance in the preclinical SF of ACI responders versus
non-responders. However, there is a marked difference between these two groups with regard to their proteome
shift in response to cartilage harvest, with 24 and 92 proteins showing ≥2.0-fold differential abundance between
Stages I and II in responders and non-responders, respectively. Proteomic data has been uploaded to
ProteomeXchange (identifier: PXD005220). We have validated two biologically relevant protein changes associated
with this response, demonstrating that matrix metalloproteinase 1 was prominently elevated and S100 calcium
binding protein A13 was reduced in response to cartilage harvest in non-responders.
Conclusions: The differential proteomic response to cartilage harvest noted in responders versus non-responders is
completely novel. Our analyses suggest several pathways which appear to be altered in non-responders that are
worthy of further investigation to elucidate the mechanisms of ACI failure. These protein changes highlight many
putative biomarkers that may have potential for prediction of ACI treatment success.
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Background
Traumatic cartilage injury can lead to the development
of osteoarthritis (OA) [1]. Autologous chondrocyte im-
plantation (ACI) has been adopted clinically to repair
cartilage damage [2, 3] and is a procedure that involves
two surgeries. The first is to harvest cartilage from a
minor load-bearing region of the joint (Stage I), followed
by a 3–4 week chondrocyte extraction and culture
expansion phase, and the second procedure (Stage II)
occurs when chondrocytes are implanted into the patho-
logical cartilage defect [3, 4]. Within our centre, the
procedure has a 19% failure rate, as defined by a lack of
improvement in Lysholm score [5], which is comparable
to other centres [6, 7]. Demographic- and injury-
associated risk factors for failure have been identified
[8–10]; however, currently there is little understanding
of the biological nature of ACI failure. We hypothesise
that an individual’s probability of failure to respond to
ACI can be predicted, and that the metrics required to
make such a prediction will come from improved under-
standing of the pathology of the failure in the first in-
stance. Further, we aim to address the need to identify
putative biomarkers that can be used to predict patient
long-term outcome prior to cartilage repair therapy. The
importance of this has been highlighted by the Osteo-
arthritis Research Society International (OARSI) who
published guidelines highlighting the need “to determine
whether biomarkers are useful in identifying those indi-
viduals most likely to receive clinically important bene-
fits from an intervention; and to determine whether
biomarkers are useful for identifying individuals at earl-
ier stages of OA in order to institute treatment at a time
more amenable to disease modification” [11]. The syn-
ovial fluid (SF) surrounding the ACI repair site provides
a biological fluid that can be assessed to profile the joint
environment and to investigate the biological response
and innate repair following a ‘controlled injury’, such as
that which is sustained at Stage I of the ACI procedure.
Despite strong evidence that unbiased proteomic ap-
proaches can identify novel biomarkers of OA progres-
sion (reviewed in De Ceuninck and Berberbaum [12]
and Hsueh et al. [13]), relatively few studies have focused
on the SF [14, 15]. The limited numbers of studies that
have analysed human SF proteins in cartilage injury and
repair have tested for markers of OA of known bio-
logical relevance to cartilage injury [16–19]. Using a
targeted approach to biomarker identification, our group
has been able to demonstrate that the absence of detect-
able aggrecanase-1 activity in the SF can be used along
with lower age and higher baseline knee function as a
predictive marker of ACI success [19], indicating that SF
biomarkers have the potential for the stratification of
patients to appropriate cartilage repair therapies. We
are unaware of any published work that has used an
untargeted approach to investigate the SF proteome be-
fore, during, or after an intervention to treat cartilage
injury. There is therefore a requirement to complete an
unbiased assessment to identify putative predictive bio-
markers that may allow for ACI patient stratification.
The broad dynamic range of proteins in SF [20, 21]
means that abundant proteins can make it difficult to
interrogate low abundance proteins by suppressing
their detectability. The deepest examination of the SF
proteome to date (equine SF) [21] used hexapeptide
libraries [22, 23] to capture low abundance proteins.
In this publication, we have profiled the SF proteome
from patients undergoing ACI treatment at both
stages of the procedure using dynamic range com-
pression with hexapeptide libraries and label-free
quantification proteomics by liquid chromatography/
tandem mass spectrometry (LC-MS/MS).
Methods
Synovial fluid collection and storage
Following local research ethical committee approval and
with informed consent, SF was collected from the knee
joints of patients at Stages I (harvest; 15 samples) and II
(implantation of cells; 24 samples) of ACI by injecting
20 mL of saline and then extending and flexing the leg
at least 20 times prior to intra-articular aspiration of as
much SF as possible [24]. SF was then centrifuged at
6000 g for 15 mins at 4 °C before being divided into
aliquots and stored in –196 °C liquid nitrogen prior to
analyses. Prior to selection of suitable patient samples
for this study, the dilution factor of the SFs was
assessed by measurement of urea concentrations in
the SF and plasma (harvested at the same time).
Based on evidence that the urea concentration of
plasma and SF is equivalent, the dilution factor could
then be calculated as described previously [19, 25].
Any samples with a dilution factor over 10 were ex-
cluded from the study.
As has previously been used [26–28], we defined re-
sponders as a minimal clinically important difference
(MCID) at approximately 12 months post-treatment if
they had an increase of 10 points in the Lysholm score
(which ranges from 0–100, with 100 representing ‘per-
fect’ knee function [29]). Fourteen SF donors were
considered as responders, with a mean improvement of
33 points (range 17–54) and 13 SF donors were consid-
ered as non-responders with a mean decrease in
Lysholm score of 14 points (range 4–46). Matched Stage
I and II samples were included for seven responders and
six non-responders; however, all of the proteomic data
presented in this study are based on non-matched sta-
tistical comparisons to ensure the maximal number of
patient samples could be included in each comparison.
The demographic information and change in Lysholm
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score for these patients is shown in Table 1. None of the
demographic parameters, other than difference in Lysholm
score between baseline and 12 months post-ACI, were sig-
nificantly different between responders and non-responders
at Stage I or Stage II, or between Stage I and Stage II in
responders or non-responders (p > 0.05; Mann-Whitney U
test; Table 1).
Sample preparation and analysis using label-free
proteomics
All SF samples were maintained as separate samples
throughout the protein equalisation, mass spectrometry,
and label-free quantification steps, and no pooling of
any samples was performed; hence, the abundance of
proteins was quantified for each of the 39 samples and
mean protein abundance across the experimental groups
was calculated prior to analysis of protein changes.
SF preparation and protein equalisation using
ProteoMiner™
The dynamic range of proteins in SF was compressed using
ProteoMiner™ beads (BioRad, Hemel Hempstead, UK) as
described previously [21]. Briefly, SF was treated with hyal-
uronidase (1 mg/ml) [21, 30] and digestion was confirmed
using a Coomassie stained 1D-SDS PAGE gel. Total protein
was quantitated using a Pierce™ 660-nm protein assay
(Thermo Scientific, Hemel Hempstead, UK) [31] and 5 mg
of total protein was exposed to ProteoMiner™ beads. After
washing, bead-bound proteins were treated with 0.05%
(w/v) RapiGest (Waters, Manchester, UK) in 25 mM
ammonium bicarbonate for 10 min at 80 °C prior to re-
duction, alkylation, and in-situ protein digestion with-
out removal of the beads, ensuring complete proteome
access. The digestion was completed in LoBind protein
tubes (Eppendorf, Stevenage, UK) followed by acidifica-
tion of trifluoroacetic acid to a final concentration of
0.5% (v/v). This treatment inactivates and precipitates the
Rapigest detergent which can then be removed by centri-
fugation. The peptide-containing supernatant fractions
were frozen at –20 °C prior to LC-MS/MS.
Mass spectrometry and label-free quantification
Tryptic peptides were subjected to LC-MS/MS, analysed
using a 2-h gradient on a NanoAcquity™ ultraperformance
LC (Waters, Manchester, UK) coupled online to a Q-
Exactive Quadrupole-Orbitrap instrument (Thermo-Fisher
Scientific Hemel Hempstead, UK) as described previously
[32]. For label-free quantification, the raw files of the ac-
quired spectra were analysed by the ProgenesisQI™ software
(Waters, Manchester, UK) [33]. Briefly, the top five spectra
for each feature were exported from ProgenesisQI™ and uti-
lised for peptide identification with a locally implemented
Mascot server (Version 2.3.01), searching against the Uni-
human reviewed database. Search parameters used were:
peptide mass tolerances, 10 ppm; fragment mass tolerance,
0.01 Da; 2+ and 3+ ions; missed cleavages, 1; enzyme,
trypsin; instrument type, ESI-FTICR. Modifications in-
cluded were: fixed carbamidomethyl cysteine and variable
Table 1 Demographic data for patient participants whose samples from Stage I or Stage II were analysed who responded clinically
(responders) or who did not respond (non-responders) to autologous chondrocyte implantation (ACI)
Stage I Stage II p value (A) R v NR SI;
(B) R v NR SI
p value (A) SI v SII
R; (B) SI v SII NRResponders
(n = 8)
Non-responders
(n = 7)
Responders
(n = 12)
Non-responders
(n = 12)
Difference in Lysholm Score 27 (17–38) –8 (–4 to –17) 34 (17–54) –11 (–4 to –46) (A) 0.0003; (B) <0.0001 (A) 0.21; (B) 0.55
BMI (kg/m2) 29 (23–31) 27 (24–31) 27 (23–48) 29 (22–36) (A) 0.94; (B) 0.54 (A) 0.73; (B) 0.68
Age (years) 32 (17–49) 40 (25–50) 40 (17–90) 43 (25–52) (A) 0.28; (B) 0.92 (A) 0.17; (B) 0.58
Male (n) 8 7 11 10 (A) >0.99; (B) >0.99 (A) >0.99; (B) 0.51
Smoker (n) 1 2 1 3 (A) 0.54; (B) 0.59 (A) >0.99; (B) >0.99
Dilution factor of SF 5 (3–9) 4 (2–7) 4 (1–9) 3 (2–5) (A) 0.48; (B) 0.25 (A) 0.53; (B) 0.50
Total defect area (cm2) 14 (0.4–24) 6 (0.6–12) 6 (1–20) 5 (0.6–12) (A) 0.74; (B) 0.35 (A) 0.45; (B) 0.28
Patella defect (n) 1 1 4 2 (A) >0.99; (B) 0.64 (A) 0.60; (B) >0.99
LFC defect (n) 2 0 0 0 (A) 0.47; (B) >0.99 (A) 0.15; (B) >0.99
LTP defect (n) 1 0 0 0 (A) >0.99; (B) >0.99 (A) 0.15; (B) >0.99
MFC defect (n) 2 2 1 6 (A) >0.99; (B) 0.07 (A) 0.54; (B) 0.63
Trochlea defect (n) 0 3 2 1 (A) 0.20; (B) >0.99 (A) 0.49; (B) 0.12
Multiple defects (n) 1 0 1 1 (A) >0.99; (B) >0.99 (A) >0.99; (B) >0.99
Unknown defect location (n) 1 1 4 2 (A) >0.99; (B) 0.64 (A) 0.60; (B) >0.99
None of the demographic parameters, other than difference in Lysholm scores, showed differences between responders (R) and non-responders (NR) in individuals
whose synovial fluids (SFs) from Stage I (SI) or Stage II (SII) were compared, nor were there differences between individuals who were either responders
or non-responders when comparing Stage I and Stage II samples (p ≥ 0.05; Mann-Whitney U test). Data are shown as median (range) unless otherwise
indicated. BMI body mass index, LFC lateral femoral condyle, LTP lateral tibial plateau, MFC medial femoral condyle
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oxidation of methionine, lysine, and proline. To maximise
the number of quantifiable proteins but simultan-
eously use an acceptable false discovery rate (FDR),
the peptide matches above an identify-threshold were
adjusted to give an FDR of 1% before the protein
identifications were re-imported into ProgenesisQI™
for the label-free relative quantification. Quantifica-
tion was undertaken using unique peptides only. Stat-
istical analysis was performed using ProgenesisQI™
software; briefly transformed normalised abundances
were used for one-way analysis of variance (ANOVA)
and all peptides (with p < 0.05) of an identified pro-
tein were included. For analysis of the proteins, the
mean abundance of each protein across the experi-
mental groups (e.g. Stage I samples from responders
etc.) was calculated and those proteins with a ≥2.0-
fold-change (FC) between the comparator groups
were reported. For use in network and pathway ana-
lysis, however, a less stringent cut-off of ≥1.2-FC was
used to allow for the study of systemic changes, as
has been appropriate in similar studies using pathway
and network approaches [34].
Pathway and network analysis of proteomic datasets
Proteins were analysed using the pathway enrichment
and topological analysis tools in Ingenuity™ (Qiagen, US)
[35] to identify and visualise the canonical pathways
which are differentially affected between Stages I and II
of ACI. To allow for greater confidence in the pathway
analysis, an independent platform, the Database for
Annotation, Visualization and Integrated Discovery (DA-
VID) [36], was used to analyse functional pathway based
on the protein changes.
Validation of mass spectrometry using ELISA
Two proteins were selected to validate the MS find-
ings because they: (1) had associated biological re-
levance to cartilage injury and repair; (2) showed
consistent differential abundance between Stages I
and II of ACI in non-responders versus responders;
and (3) could be measured using available enzyme-
linked immunosorbent assays (ELISAs). These pro-
teins, matrix metalloproteinase 1 (MMP1) [37] and
S100 calcium binding protein A13 (S100-A13) [38],
were quantified using duo-set ELISAs (R&D systems,
Wiesbardon, Germany) according to the manufac-
turer’s instructions. Samples were assessed in dup-
licate and mean optical density values were used to
calculate the protein concentration. SF was diluted
1:2 and 1:100 for the assessment of MMP1 and S100-
A13, respectively. The protein concentration of each
protein was normalised to total protein concentration.
Statistical analysis was performed in GraphPad Prism
version 6.0.
Results
Proteomic data has been deposited in the PRIDE Proteo-
meXchange and can be accessed using the identifier
PXD005220 [39].
Differential abundance of proteins in responders versus
non-responders to ACI
Proteomic analysis identified that Ig kappa chain V-II region
MIL demonstrated a +2.6-FC in non-responders versus
responders to ACI in SF at Stage I (Fig. 1a). Nine proteins
demonstrated differential abundance at Stage II between
responders and non-responders (26S protease regulatory
subunit 7, +2.3-FC; 26S proteasome non-ATPase regulatory
subunit 13, +2.4-FC; ferritin light chain, +2.9-FC; platelet
factor 4, +3.3-FC; thrombospondin-1, +3.4-FC; nucleosome
assembly protein 1-like 1, +4.9-FC; cofilin-1, +7.1-FC; EH
domain-containing protein 1, +7.3-FC; and T-complex
protein 1 subunit eta, +8.4-FC) (Fig. 1a).
Differential abundance of proteins after controlled
cartilage injury (Stage I versus Stage II)
When comparing Stage I with Stage II, 116 proteins
were >2.0-fold differentially abundant. Non-responders
to ACI displayed a distinct and marked response to
Stage I surgery, such that between Stages I and II, 33
proteins were upregulated and 59 downregulated, 12 of
which demonstrated common expression change in
clinical responders to ACI (Table 2; Fig. 1b). Fifteen
proteins were upregulated and nine proteins were down-
regulated between Stage I and Stage II in responders to
ACI (Table 3; Fig. 1b).
Identification of canonical pathways and protein
networks associated with protein changes between Stage
I and II
Several canonical pathways were associated with the pro-
tein changes identified in both clinical responders and
non-responders (Fig. 2). Figure 3, however, highlights the
disparity in the proteome response to Stage I between
clinical responders and non-responders, as a much greater
number of functional/disease pathways were activated or
inhibited in association with these differentially abundant
proteins. Using Ingenuity software, canonical pathways
that were most significantly connected with these protein
changes in non-responders were Liver X Receptor/Retin-
oic X receptor (LXR/RXR) activation (p = 1.63 × 10–7),
complement system (p = 9.33 × 10–7), and acute phase re-
sponse signalling (p = 1.69 × 10–6) (Fig. 2). Independent
pathway analysis of the proteins using DAVID also
highlighted the complement system (p = 2.1 × 10–6) as
highly associated with the protein changes seen between
Stages I and II of ACI in non-responders.
The Stage I versus Stage II responder network consisted
predominantly of proteins associated with connective
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tissue disorders (p = 8.2 × 10–7). In non-responders to
ACI, however, the top scoring network included
several proteins associated with the inflammatory re-
sponse (p = 2.75 × 10–5) (Fig. 4). Transforming growth
factor beta 1 (TGFβ1) and CCAAT/enhancer-binding
protein beta were predicated to be the most significant
upstream regulators associated with the networks of
protein changes identified between Stages I and II in non-
responders and responders, respectively (Table 4).
TGFβ was also predicted as an upstream regulator of
the protein changes identified between Stages I and II
in responders; therefore, it may be important in the
regulation of protein response between Stages I and
II, irrespective of outcome.
Measurement of MMP1 and S100-A13 protein in SF by
ELISA
MMP1 and S100-A13 protein abundance in SF from
the same patient cohort was measured using ELISA.
Biochemical assessment replicated the MS finding that
SF MMP1 concentration is significantly increased at
Stage II in non-responders (Stage I, 800 ± 889 pg/ml;
Stage II, 7741 ± 8065 pg/ml (mean ± SD); p = 0.006;
Mann-Whitney U test) (Fig. 5). However, mea-
surement of MMP1 via ELISA also demonstrated a
significant increase in concentration at Stage II com-
pared to Stage I in responders to ACI (albeit to a lesser
order of magnitude: Stage I, 655 ± 837 pg/ml; Stage II,
2672 ± 3576 pg/ml (mean ± SD); p = 0.039; Mann-Whitney
U test) (Fig. 5). In this patient cohort, no correlation be-
tween Lysholm score and MMP1 could be demonstrated
(r = 0.02; p = 0.94; Spearman’s correlation).
Biochemical quantification identified a significant de-
crease in S100-A13 expression at Stage II (94 ± 31 pg/ml
(mean ± SD)) compared to Stage I (245 ± 123 pg/ml
(mean ± SD); p =0.02; Mann-Whitney U test) of the ACI
process in clinical non-responders and no significant dif-
ference in responders (Stage I, 200 ± 118 (mean ± SD);
Fig. 1 Venn-Diagrams representing the proteins identified using label-free quantification proteomics which were differentially abundant (≥2.0-FC)
in the SF (a) at Stage I (SI) or Stage II (SII) in responders (R) compared to non-responders (NR) to ACI, (b) showing increased (↑) or decreased (↓)
abundance at Stage II compared to stage I of ACI in clinical responders (R) or non-responders (NR)
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Table 2 Fold-change of proteins that are differentially expressed
in the synovial fluid collected at Stage I compared to Stage II of
the ACI procedure in clinical non-responders. Proteins shown in
italic were validated using enzyme linked immunosorbant assay
Protein Fold change
Description Accession
Perilipin-4 Q96Q06 –4.3
Syntaxin-7 O15400 –3.9
Fermitin family homolog 3 Q86UX7 –3.7
Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Q9Y3Z3 –3.7
PDZ and LIM domain protein 1 O00151 –3.6
Sorting nexin-5 Q9Y5X3 –3.3
Neuroblast differentiation-associated protein AHNAK Q09666 –3.2
Signal recognition particle 14 kDa protein P37108 –3.0
Hyaluronan and proteoglycan link protein 3 Q96S86 –3.0
Heterogeneous nuclear ribonucleoprotein K P61978 –2.9
ATP-citrate synthase P53396 –2.9
Fatty acid-binding protein, epidermal Q01469 –2.8
60S ribosomal protein L12 P30050 –2.7
Fatty acid-binding protein, adipocyte P15090 –2.6
Insulin-like growth factor-binding protein 6 P24592 –2.6
Protein canopy homolog 3 Q9BT09 –2.6
Tripeptidyl-peptidase 1 O14773 –2.5
PDZ and LIM domain protein 3 Q53GG5 –2.5
Cellular nucleic acid-binding protein P62633 –2.5
Bifunctional glutamate/proline-tRNA ligase P07814 –2.5
Protein disulfide-isomerase A3 P30101 –2.4
Peroxiredoxin-6 P30041 –2.4
Tryptase alpha/beta-1 Q15661 –2.4
Endoplasmic reticulum resident protein 29 P30040 –2.4
Peroxiredoxin-1 Q06830 –2.4
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 O14745 –2.4
Mitochondrial import inner membrane translocase subunit
TIM14
Q96DA6 –2.4
Mortality factor 4-like protein 1 Q9UBU8 –2.4
Fructose-bisphosphate aldolase A P04075 –2.3
Microtubule-associated protein RP/EB family member 1 Q15691 –2.3
Leucine zipper transcription factor-like protein 1 Q9NQ48 –2.3
Transcription elongation factor A protein 1 P23193 –2.3
2',3'-cyclic-nucleotide 3'-phosphodiesterase P09543 –2.3
Histamine N-methyltransferase P50135 –2.3
Protein S100-A13 Q99584 –2.3
Acrosomal protein SP-10 P26436 –2.2
AP-2 complex subunit beta P63010 –2.2
S-phase kinase-associated protein 1 P63208 –2.2
High mobility group protein B3 O15347 –2.2
Cytokine-like protein 1 Q9NRR1 –2.2
Mitochondrial fission 1 protein Q9Y3D6 –2.2
Filamin-A P21333 –2.2
Nuclear migration protein nudC Q9Y266 –2.1
Cathepsin K P43235 –2.1
Prostaglandin E synthase 3 Q15185 –2.1
Vinculin P18206 –2.1
Table 2 Fold-change of proteins that are differentially expressed
in the synovial fluid collected at Stage I compared to Stage II of
the ACI procedure in clinical non-responders. Proteins shown in
italic were validated using enzyme linked immunosorbant assay
(Continued)
Plastin-2 P13796 –2.1
Coronin-1C Q9ULV4 –2.1
Ig heavy chain V-I region V35 P23083 –2.1
Stress-induced-phosphoprotein 1 P31948 –2.1
Putative phospholipase B-like 2 Q8NHP8 –2.1
Gelsolin P06396 –2.0
Spectrin beta chain, erythrocytic P11277 –2.0
Stathmin P16949 –2.0
Hsc70-interacting protein P50502 –2.0
40S Ribosomal protein P23396 –2.0
Epidermal growth factor receptor substrate 15 P42566 22.5
Hemoglobin subunit theta-1 P09105 6.1
C-type lectin domain family 11 member A Q9Y240 5.6
Periostin Q15063 5.1
Collagen alpha-1(I) chain P02452 4.7
Spectrin alpha chain, erythrocytic 1 P02549 4.0
Collagen alpha-1(V) chain P20908 3.7
Fibrinogen gamma chain P02679 3.5
Collagen alpha-1(XII) chain Q99715 3.3
Complement C1q tumor necrosis factor-related protein 3 Q9BXJ4 3.1
Adiponectin Q15848 3.0
Adipocyte enhancer-binding protein 1 Q8IUX7 3.0
Latent-transforming growth factor beta-binding protein 1 Q14766 3.0
Fibrinogen beta chain P02675 3.0
Chondroitin sulfate proteoglycan 4 Q6UVK1 2.9
Fibrinogen alpha chain P02671 2.8
Interstitial collagenase (MMP1) P03956 2.7
Secreted phosphoprotein 24 Q13103 2.7
Collagen alpha-2(V) chain P05997 2.6
Ferritin light chain P02792 2.6
C4b-binding protein alpha chain P04003 2.6
Nucleobindin-1 Q02818 2.4
C4b-binding protein beta chain P20851 2.2
Vitamin K-dependent protein S P07225 2.2
Fibronectin P02751 2.2
Prosaposin P07602 2.1
Integrin beta-like protein 1 O95965 2.1
Adipocyte plasma membrane-associated protein Q9HDC9 2.1
Cytoplasmic dynein 1 heavy chain 1 Q14204 2.0
Soluble scavenger receptor cysteine-rich domain-containing
protein SSC5D
A1L4H1 2.0
F-actin-capping protein subunit beta P47756 2.0
Mannan-binding lectin serine protease 1 P48740 2.0
Thrombospondin-3 P49746 2.0
Positive numbers denote an increase in the protein at Stage II; negative numbers
denote a decrease in the protein at Stage II
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Stage II, 138 ± 93 (mean ± SD); p = 0.2; Mann-Whitney U
test) thus validating MS findings (Fig. 5). To assess
whether the differential abundance of S100-A13 identified
between Stages I and II was genuinely only a response of
clinical non-responders, further statistical analysis includ-
ing only the paired Stage I (n = 7) and II (n = 6) samples
was completed. The paired analysis also confirmed the
MS findings, with non-responders having lower SF S100-
A13 concentration at Stage II compared to Stage I (Stage
I, 270 ± 113 (mean ± SD); Stage II, 116 ± 112 (mean ± SD);
p = 0.03; Wilcoxon-matched pairs) and no significant dif-
ference in S100-A13 concentration between Stages I and
II demonstrated in clinical responders (Stage I, 204 ± 127
(mean ± SD); Stage II, 140 ± 53 (mean ± SD); p = 0.22;
Wilcoxon-matched pairs). Again, Lysholm score and
S100-A13 concentration did not correlate in this cohort
(r = 0.0002; p = 0.99; Spearman’s correlation).
Discussion
The unbiased quantitative study of the human SF prote-
ome is relatively limited [14, 15] and few studies are
reported which identify novel biomarkers for the diagno-
sis of cartilage injury or for their prognostic or predictive
value in the treatment of cartilage injuries [16, 18]. To
our knowledge, only four studies have assessed SF or
blood for biomarkers of cartilage injury treatment
[16, 17, 19, 40] from which limited putative predict-
ive markers have been identified.
The patient cohort used in this study presents an op-
portunity to explore which proteins are altered between
individuals who have responded well to ACI and those
non-responders whose joint function has deteriorated
post-treatment. Although a non-responder is generally
defined as an individual who does not demonstrate an
improvement in Lysholm score of 10 or more points, we
have been able to identify proteins that relate to the
worst clinical outcomes in our cohort; in future studies,
these protein changes will need to be explored further in
non-responders with a lesser negative response to ACI.
It would have been interesting to assess how cartilage re-
generation related to clinical outcome in these patients;
unfortunately, however, data regarding the quality and
amount of repair tissue in the defect site post-treatment
were not routinely collected for these patients.
Ideally, a biomarker that predicts response to cell ther-
apy would be measured before the patient undergoes
cartilage harvest. This study, however, demonstrated that
only one protein displayed differential abundance between
responders and non-responders at Stage I of the ACI
procedure. Interestingly, the vast majority of differences in
the proteomic profile of SF were evident between Stages I
and II of the ACI procedure, particularly in non-
responders to ACI. Analysis of the pathways that are
altered between Stages I and II of ACI illustrates further
the disparity in biological response to a controlled cartil-
age injury in clinical responders versus non-responders.
This suggests that it may be the response of the patients
to the cartilage harvest procedure at Stage I that proves to
be the best predictor of clinical outcome.
One of the biologically relevant proteins identified that
increased in the SF of non-responders at Stage II compared
to Stage I of ACI was MMP1. Along with other MMP fam-
ily members, it is overexpressed in many forms of arthritis
[37] and has been strongly associated with increased joint
inflammation [41, 42]. Since MMP1 has cartilage degrad-
ation properties [37], implanting chondrocytes into a joint
with high levels of active MMP1 might be detrimental to
any new cartilage formation. However, the ELISA used in
this study assessed total MMP1 protein; therefore, add-
itional studies to determine how much active MMP1 is
present would be needed to further elucidate the mecha-
nisms of action. Nonetheless, a higher absolute level of
Table 3 Proteins that are differentially expressed with a ≥2.0-fold-
change in the synovial fluid collected at Stage I compared to
Stage II of the ACI procedure in clinical responders
Protein Fold change
Description Accession
Heat shock protein 75 kDa, mitochondrial Q12931 –470.0
Microtubule-associated protein 1B P46821 –17.2
Adenosylhomocysteinase P23526 –3.7
Complement factor H-related protein 3 Q02985 –2.8
Mannose-1-phosphate guanyltransferase beta Q9Y5P6 –2.7
Peroxiredoxin-4 Q13162 –2.5
Oxysterol-binding protein 1 P22059 –2.4
Protein canopy homolog 3 Q9BT09 –2.1
Spermatid perinuclear RNA-binding protein Q96SI9 –2.0
Ferritin light chain P02792 2.2
Secreted phosphoprotein 24 Q13103 2.2
Chondroitin sulfate proteoglycan 4 Q6UVK1 2.3
Collagen alpha-2(I) chain P08123 2.3
Collagen alpha-1(V) chain P20908 2.5
26S protease regulatory subunit 6A P17980 2.7
Collagen alpha-2(V) chain P05997 2.9
Collagen alpha-1(I) chain P02452 3.3
Spectrin alpha chain, erythrocytic 1 P02549 4.1
Histidine triad nucleotide-binding protein 1 P49773 4.2
Platelet factor 4 P02776 4.2
Alpha-1-acid glycoprotein 2 P19652 4.3
Protein 4.1 P11171 4.3
Periostin Q15063 4.5
26S proteasome non-ATPase regulatory
subunit 13
Q9UNM6 4.6
Positive numbers denote an increase in the protein at Stage II, negative
numbers denote a decrease in the protein at Stage II
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MMP1 found in the SF of non-responders at Stage II com-
pared to Stage I of the ACI procedure is suggested to be
predictive of a poor outcome, which could inform the
second stage of the ACI procedure. For example, it may be
that an individual with high levels of MMP1 at Stage II
requires a tailored procedure and could benefit from de-
layed chondrocyte implantation to allow for dampening of
inflammation or a coincidental treatment to reduce MMP1
activity specifically or to reduce joint inflammation.
Interestingly, S100-A13 abundance was found to be sig-
nificantly lower in the SF from non-responders to ACI at
Stage II compared to Stage I. This finding is completely
novel since, despite six of these family members having
been studied in cartilage (S100B [43], S100-A2 [44], S100-
A4 [45], S100-A8 [46], S100-A9 [46], and S100-A11 [47]),
we are unaware of any studies that have assessed the role
of S100-A13 in cartilage or SF. S100-A13 therefore pre-
sents an attractive novel candidate for further study, not
only to confirm its potential as a predictive biomarker but
also to improve our biological understanding of the
processes underlying cartilage injury and repair.
Despite MMP1 and S100-A13 both having potential as
candidate biomarkers to determine whether or not a pa-
tient is suitable to continue to the second stage of ACI,
it is unlikely that any individual biomarkers will be suffi-
cient to determine which patients are suitable candidates
for a cartilage repair therapy. Patient demographics have
already been identified which are known to pre-dispose
to ACI failure, including gender, body mass index, age,
and the size of the cartilage lesion [10, 25, 48]. Our
long-term aim is to work towards the development of a
clinical prediction model which will likely include known
risk factors, along with a panel of biomarkers that,
together, can predict the response of an individual to
ACI. This exploratory study has indicated a plethora of
potential SF biomarkers that may contribute to the
Fig. 2 Canonical pathways altered in the synovial fluid of responders (a) and non-responders (b) at Stage I compared to Stage II of ACI, identified using
Ingenuity analysis, based on proteins which were identified using label-free quantification proteomics (≥1.2-FC). The bars represent the significance of the
canonical pathway as calculated by a right-sided Fisher’s exact test; therefore, the tallest bars represent the canonical pathways that are the least likely to
have been identified due to molecules being in the canonical pathway by random chance. Canonical pathways which are likely activated (based on the
pattern of differentially abundant proteins) are shown in orange and pathways that are likely inhibited are shown in blue
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development of such a clinical prediction model. Other
studies have also indicated that the quality of the
culture-expanded autologous chondrocytes affects pa-
tient clinical outcome (higher percentage positivity of
CD44-expressing cells and increased collagen type II
and aggrecan expression correlate with good clinical
outcome, whereas lower cell viability correlates with
poor clinical response to ACI) [28, 49, 50]. Therefore,
ideally, the quality of ACI cells prior to implantation at
Stage II, along with known demographic risk factors,
would be considered as part of a clinical prediction
matrix. We have already shown that the absence of de-
tectable aggrecanse-1 is able to predict ACI success, and
that lower age and the use of a collagen patch are also
indicators of ACI success [19]; consequently, markers
identified within this study may be added to this devel-
oping predictive model.
Many of the protein shifts observed in the SF between
Stages I and II of the ACI procedure are likely to be as-
sociated with acute mechanisms of cartilage healing in
response to the cartilage harvest, which could be consid-
ered as a controlled injury. Furthermore, the differences
observed in this shift when comparing responders and
non-responders to ACI could be a result of differences
in the mechanisms of action and/or the rate/magnitude
of an individual’s innate capacity for cartilage healing.
Our evaluation of the SF proteome shift both before and
after such a defined injury represents a period of acute
response to injury and could therefore be considered as
a model of short-term natural healing in humans. In
order to validate that the response observed in this
model is due to the cartilage harvest and not the arthro-
scope procedure, an appropriate control group should
be evaluated. In future work we will aim to test potential
Fig. 3 Heat map showing canonical pathway groupings for molecular and cellular functions altered in the synovial fluid of responders (a) and
non-responders (b) at Stage I compared to Stage II of ACI, identified using Ingenuity analysis, based on proteins which were identified using
label-free quantification proteomics (≥1.2-FC). Squares are coloured based on their z score, with orange being up at Stage II and blue being down
at Stage II; the colour intensity indicates the prediction strength. The z score represents whether the up- or downregulation of the proteins within
that function will lead to activation (positive z score) or inhibition (negative z score) of the function. Black boxes are shown around functions of
biological interest: cellular movement, haematological system development and function, immune cell trafficking, and inflammatory response
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Fig. 4 Top scoring networks derived from the proteins with different abundance (≥1.2-FC) at Stage II compared to Stage I of the autologous
chondrocyte implantation (ACI) procedure in those who responded well clinically (responders; a) and those who did not respond clinically
(non-responders; b). Red nodes represent greater protein abundance at Stage II of ACI; green nodes represent lower protein abundance at Stage II of
ACI; and white nodes represent inferred proteins which are not differentially expressed between Stage I and Stage II (based on label-free quantification
proteomic analysis). The key to the features within the network is shown. APOB Apolipoprotein B-100, CD3 T-cell surface glycoprotein CD3, Ck2 Casein
kinase 2, COL1A1 Collagen alpha-1(I) chain, COL1A2 Collagen alpha-2(II) chain, C4 Complement C4, DYNC1H1 Cytoplasmic dynein 1 heavy chain 1, ERK
Mitogen-activated protein kinase 3, ERP29 Endoplasmic reticulum resident protein 29, F7 Coagulation factor VII, FCN3 Ficolin-3, GABRAPL2 Gamma-
aminobutyric acid receptor-associated protein-like 2, GBA Glucosylceramidase, GMFB Glia maturation factor beta, GPLD1 Phosphatidylinositol-glycan-
specific phospholipase D, HINT1 Histidine triad nucleotide-binding protein 1, HDL-cholesterol High density lipoprotein-cholesterol, HMGB2 High mobility
group protein B2, HSP76 Heat shock protein 76, IGFBP6 Insulin-like growth factor binding protein 6, Jnk Mitogen-activated protein kinase, LCAT
Phosphatidylcholine-sterol acyltransferase, LDL Low-density lipoprotein receptor, LTF Lactotransferrin, MASP1 Mannan-binding lectin serine protease 1,
MASP2 Mannan-binding lectin serine protease 2, MYH10 Myosin-10, MYLK Myosin light chain kinase, smooth muscle, NFkB complex nuclear factor
kappa-light-chain-enhancer of activated B cells complex, PAM Peptidyl-glycine alpha-amidating monooxygenase, PDCD6IP Programmed cell death
6-interacting protein, PF4 Platelet factor 4, PI3K complex Phosphoinositide-3 kinase complex, PLG Plasminogen, POSTN periositin, PSMA7 Proteasome
subunit alpha type-7, P38 MAPK P38 mitogen-activated protein-kinases, Rock Rho-associated protein kinase 1, RPL22 60S ribosomal protein L22, Rxr
retinoic X receptor, STX7 Syntaxin-7, Tgf beta Transforming growth factor beta, Vegf Vascular endothelial growth factor
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biomarkers in a stem cell treatment group which will
similarly undergo a Stage I arthroscope (but without a
cartilage harvest) followed by cell implantation at Stage
II in a comparable time frame.
Pathway and network analyses were performed to try and
elucidate the functional implications of the observed prote-
ome shift. Confidence can be taken from these findings, as
pathways of known biological relevance were identified. For
example, the complement system, which was activated in
non-responders to ACI, can lead to cartilage degradation
[47]. Other biologically relevant pathways that were identi-
fied include the acute phase response, which in contrast
was dysregulated in non-responders. Dysregulation of the
acute phase response has previously been associated with
the proteome of OA knees [51], and serum amyloid-A, a
key acute-phase protein, is increased in abundance in the
SF and blood of individuals with OA [52]. Both of these
observations indicate that the acute-phase response may be
a contributing factor as to why some individuals do not
respond well to ACI and there is merit in further studying
how this pathway is altered in these individuals.
Interestingly, TGFβ1 was suggested as the most po-
tent potential upstream regulator of the network of
non-responder SF protein response to ACI. TGFβ1 is
suggested to regulate twenty-seven of the network
proteins, and therefore manipulation of this biological
network via TGFβ1 may serve as a potential method to
influence response to ACI in clinical non-responders. It is
strongly established that TGFβ signalling is highly in-
fluential on the development and progression of OA
[53]. Specifically, TGFβ is important in the regulation
of chondrocyte hypertrophy and maturation [54].
Mutations in the TGFβ1 gene, as well as genetic vari-
ation in other members of the TGFβ signalling path-
way, have been related to OA development [53].
Moreover, in transgenic animals which overexpress
the type-II TGFβ receptor, chondrocytes in the super-
ficial zone of the cartilage are hypertrophic with in-
creased type X collagen expression and decreased
proteoglycans [55]. Together, these observations high-
light the importance of TGFβ for chondrocyte ho-
meostasis; therefore, in non-responders to ACI, perhaps
Table 4 Analysis of upstream regulators of interactome networks generated from protein changes between Stages I (SI) and II (SII)
in either responders or non-responders to ACI were identified using Ingenuity Pathway Analysis software
Upstream regulators Activation z score (SII v SI) p value of overlap Target molecules in dataset
Non-responders
TGFB1 –1.595 9.46E–10 APOB,APOC2,APOE,CD44,COL1A1,COL1A2,COL5A1,COMP,CSPG4,CTSD,ECM1,FETUB,FN1,
FTL,GSN,HINT1,HSPG2,HTRA1,IGFBP6,LCAT,MYLK,PCOLCE2,PDXK,POSTN,RAP1A,S100A4,TGFBI
DYSF NP 2.01E–09 CFD,FN1,FTL,LCP1,LYZ,PROS1,S100-A13,S100A4
MYC 3.046 2.20E–09 ALDOA,ANXA5,CCT3,CD44,COL1A1,COL1A2,COL5A1,CSPG4,CTSD,ECM1,FN1,HSPA9,LYZ,NCL,NUCB1,
NUDC,PAM,PTN,RPL22,RPL30,TF
COL9A1 1.308 2.79E–09 COMP,FN1,HSPG2,TGFBI,THBS4
Beta-estradiol 2.271 5.01E–09 ALDOA,APOE,CD44,COL1A1,COL1A2,COMP,CTSD,F7,FN1,GMFB,HSPA2,HSPA8,HSPA9,HTRA1,IGFBP6,
LTF,LYZ,MYLK,PAM,PDIA3,QSOX1,RAP1A,RPS13,S100-A13,SLC9A3R1,TF,THBS4
Lipopolysaccharide –0.104 5.96E–09 ANXA5,APOB,APOC2,APOE,CD44,CFD,COL1A1,COL1A2,COL5A1,CSPG4,FN1,GSN,HDGFRP3,HMGB2,
HSPA8,HTRA1,ITIH2,LBP,LTF,LYZ,PARK7,PCOLCE,PCOLCE2,PDIA3,PLG,TF
Dihydrotestosterone –1.091 1.03E–08 ALDOA,APOE,CCT3,FN1,FTL,GSN,HINT1,LYZ,MYLK,NUCB1,PAM,POSTN,PROS1,RPL30,TF
HRAS 0.623 2.52E–08 CD44,COL1A1,COL1A2,ERP29,FN1,GSN,HSPA8,HTRA1,LYZ,MYH10,PDIA5,PLTP,POSTN,RPL30,S100A4
KRAS 2.226 3.99E–08 ALDOA,CD44,COL1A1,FN1,GBA,GSN,MYLK,PCOLCE,PDIA3,PSMA7,RNASE4,S100A4
SMARCB1 –1.195 4.82E–08 APOC4,CD44,COL1A1,COL1A2,GSN,LBP,POSTN,PTN,RAB14
Responders
CEBPB –1.067 2.03E–07 APOB,CFD,COL1A1,COL1A2,F7,HSPA8,PLG
FLI1 NP 3.82E–07 COL1A1,COL1A2,HSPA8,PF4
S-adenosylhomocysteine NP 1.21E–06 COL1A1,COL1A2
SCX NP 1.65E–06 COL1A1,COMP,POSTN
Tgf beta (group) –1.454 5.16E–06 COL1A1,COL1A2,LCAT,POSTN,TGFBI
ENTPD5 NP 1.21E–05 COL1A1,COL1A2
MKX NP 1.21E–05 COL1A1,COL1A2
GATA4 NP 2.86E–05 COL1A1,COL1A2,POSTN,TGFBI
Nilotinib NP 3.39E–05 COL1A1,COL1A2
TBX5 NP 5.50E–05 COL1A1,COL1A2,POSTN
The 10 upstream regulators with the lowest p values are demonstrated for both responders and non-responders. The p value of overlap is calculated based on the overlap
between protein changes within the dataset with known targets of the transcriptional regulator, calculated using a Fisher’s exact test. The activation z score can be used to
infer likely activation states of the upstream regulators based on the direction of protein abundance change in the dataset, i.e. a negative activation z score indicates that the
upstream regulator is downregulated at Stage II compared to stage I, thus eliciting the specific directions of protein changes of the target molecules at Stage II compared to
Stage I of ACI. NP indicates no prediction of activation status could be generated by the software
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aberrant upstream expression of TGFβ contributes to
their poor cartilage formation.
Canonical pathway analysis has also highlighted more
novel pathway modifications within non-responders to
ACI such as inhibition of LXR/RXR. Dimerisation of
RXRs and LXR initiates transcriptional regulation
that is involved in the regulation of inflammation
[56]. Interestingly, proteomic profiling of the SF from
osteoarthritic shoulders has highlighted dysregulation
of the LXR/RXR pathway in response to OA [57], and
agonism of the LXR/RXR pathway has previously
been suggested as a therapeutic target for OA since
human cartilage explants treated with a synthetic
LXR agonist showed reduced cytokine-mediated degrad-
ation of proteoglycans [58]. Although further study is
required to determine how inhibition of the LXR/RXR
pathway may lead to a poor clinical response to ACI, it
may be that these individuals are demonstrating a more
‘osteoarthritic’ phenotype, perhaps meaning that ACI may
be insufficient to repair their cartilage injury.
The most striking biologically relevant canonical path-
way groupings that were upregulated in non-responders
to ACI were inflammatory and immune responses. This
strengthens the suggestion that poor response to ACI in
these individuals may be attributed to the chondrocytes
being implanted into an unsuitable, highly inflammatory
environment. Alternatively, it may indicate that these
individuals have a more pronounced immune reaction to
cartilage injury in general, and that this is an indicative
response of ‘poor healers’.
Fig. 5 Two biologically relevant proteins, matrix metalloproteinase-1 (MMP1) and S100 calcium binding protein A13 (S100-A13), that were identified by
proteomic analysis as differentially abundant in the SF of non-responders between Stages I (SI) and II (SII) of the ACI procedure were validated by ELISA.
a The differential abundance as measured by label-free mass-spectrometry and by biochemical ELISA. MMP1 was measured by ELISA in the SF of (b)
non-responders (NR) and (c) responders (R) to ACI at cartilage harvest (Stage I; S1) and chondrocyte implantation (Stage II; S2). S100-A13 was measured
by ELISA in the SF of non-responders (d) and responders (e) to ACI
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Conclusion
We have identified proteins that are altered within the SF
following cartilage injury and ACI, and have highlighted
proteome changes in response to the cartilage harvest
procedure in ACI which relates to clinical outcome. These
protein changes represent a plethora of potential predict-
ive biomarkers that, with further validation, could help in
the identification of patients who are not suited to ACI or
perhaps any cartilage repair procedure. Pathway and net-
work analyses of the altered SF proteome have highlighted
both known and novel biological pathways that may be
implicated in the response to Stage I of ACI. These data
present an opportunity for future study which could vastly
improve our knowledge of how a joint responds to cartil-
age injury and how that may differ between individuals
who do or do not have the capacity for cartilage repair.
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